New combo therapy aims to knock out high-risk prostate cancer
NCT ID NCT05568550
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study is for men with high-risk prostate cancer that hasn't spread. It tests whether adding an immunotherapy drug (pembrolizumab) and a targeted drug (olaparib) to standard radiation therapy can better control the cancer. About 64 participants will receive the combination and be monitored for treatment response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute
ACTIVE_NOT_RECRUITINGSalt Lake City, Utah, 84112, United States
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?